There are currently 1983 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis(GHOA)
NCT04949087
Recruiting
The purpose of this study is to compare the efficacy of intra-articular corticosteroid injections versus platelet-rich plasma injections for non-operative treatment of primary glenohumeral osteoarthritis. The efficacy of intra-articular injections, outside of hyaluronic acid, for the treatment of glenohumeral OA is not known, yet these treatments are commonly used with hopes of providing patients with symptomatic relief that can hopefully delay or prevent the need for shoulder arthroplasty. This... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Arthritis Shoulder
Register for Updates
Study of Individuals Affected With Hypoplasminogenemia
NCT03797495
Recruiting
This is an Investigator initiated retrospective and prospective single cohort study. The study will utilize an international registry and develop a specimen biobank to provide an improved understanding of the natural history of hyposplasminogenemia, to elucidate the heterogeneity of phenotypic expression, identify markers to predict disease course, and inform improved therapeutic modalities
Gender:
ALL
Ages:
All
Trial Updated:
10/30/2024
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Plasminogen Deficiency
Register for Updates
Bowel Function After Minimally Invasive Hysterectomy
NCT04263896
Recruiting
Postoperative constipation affects up to a third of women undergoing minimally invasive (MIS) gynecologic surgery and is a major source of anxiety and discomfort. The average time to first bowel movement after gynecologic surgery is about 2 to 4 days and some factors responsible for this include anesthesia inhibitory effect on gastrointestinal motility, opioid pain medication use, chronic NSAID use and anatomic manipulation. There are no established regimens to manage postoperative constipation... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: University of Chicago Medicine, Chicago, Illinois
Conditions: Constipation
Register for Updates
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
NCT04762979
Recruiting
Patients who have histologically confirmed metastatic or unresectable (not amenable to curative therapy) breast cancer may be screened for eligibility. All patients must have HER2 negative breast cancer with the identified PIK3CA mutation and received at least one line of endocrine therapy. The study will consist of a screening phase, a treatment phase, and a post-treatment phase which includes safety, efficacy, and follow-up. The treatment phase will include taking alpelisib daily in combinatio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: University of Illinois Cancer Center, Chicago, Illinois
Conditions: Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer
Register for Updates
rTMS to Improve Cognition in Parkinson's
NCT03836950
Recruiting
The purpose of this study is to examine safety, feasibility, and the behavioral and brain effects of a non-invasive treatment, repetitive transcranial magnetic stimulation (rTMS), for Veterans with Parkinson's disease or atypical parkinsonism and mild impairments in their thinking. The hypothesis is that rTMS can improve thinking for people with Parkinson's disease or atypical parkinsonism who are experiencing mild problems with their thinking ability.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
10/28/2024
Locations: Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois
Conditions: Parkinson's Disease, Mild Cognitive Impairment
Register for Updates
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
NCT06014255
Recruiting
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical prostatectomy or standard of care arms.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Northewestern University, Chicago, Illinois
Conditions: Prostate Cancer
Register for Updates
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children with Generalized Myasthenia Gravis
NCT04833894
Recruiting
The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG. Trial details include: * The maximum trial duration for each individual participant will be approximately 28 weeks * The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18 weeks for the treatment response-confirmatory part (Part B)
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
10/28/2024
Locations: Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois
Conditions: Generalized Myasthenia Gravis
Register for Updates
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma
NCT06571734
Recruiting
This phase II trial tests how well zanzalintinib (XL092) works in treating patients with leiomyosarcoma that has spread from where it first started to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Leiomyosarcomas are a type sarcoma that can occur in any location in the body, such as the uterus or in the abdomen. Current standard treatment for leiomyosarcoma only shows a progression-free survival of 4-6 months. XL092, a tyrosine kinase inhibitor, inter... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma
Register for Updates
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
NCT05184569
Recruiting
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/28/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Semantic Dementia
Register for Updates
Clinical Decision Support Tool in PARDS Pilot Study
NCT04068012
Recruiting
Previous clinical trials in adults with acute respiratory distress syndrome (ARDS) have demonstrated that ventilator management choices can improve Intensive Care Unit (ICU) mortality and shorten time on mechanical ventilation. This study seeks to scale an established Clinical Decision Support (CDS) tool to facilitate dissemination and implementation of evidence-based research in mechanical ventilation of infants and children with pediatric ARDS (PARDS). This will be accomplished by using CDS t... Read More
Gender:
ALL
Ages:
Between 1 month and 18 years
Trial Updated:
10/28/2024
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Ventilation Therapy; Complications, Ventilator-Induced Lung Injury, Ards
Register for Updates
CEDARS Intervention: A Coping, Emotional Development, & Stress Reduction Intervention
NCT04958694
Recruiting
Using an adapted stress-reduction intervention called the CEDARS, the investigators will pilot the intervention in adolescents (N=40) to determine the feasibility and acceptability of CEDARS implementation and to investigate adolescent stress reduction. As an exploratory aim, the investigators will explore the influence of the CEDARS on CMH-related behaviors and CMH. The investigators expect that those adolescents who undergo the intervention will have the greatest improvement in mental health s... Read More
Gender:
ALL
Ages:
Between 14 years and 19 years
Trial Updated:
10/28/2024
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Adolescent Behavior, Stress Reduction, Adverse Childhood Experiences, Positive Attitude
Register for Updates